TLSA — Tiziana Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- $79.78m
- $62.03m
- 33
- 15
- 52
- 25
Annual balance sheet for Tiziana Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.31 | 0.203 | 65.9 | 42.2 | 18.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.29 | 1.14 | 3.83 | 6.38 | 5.99 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6.65 | 1.52 | 70.3 | 48.7 | 24.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.008 | 0.593 | 0.36 | 0.017 | 0.389 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.93 | 2.4 | 70.8 | 48.8 | 26.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.41 | 7.39 | 7.99 | 7.55 | 6.66 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 6.41 | 7.94 | 8.28 | 7.55 | 6.91 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 0.524 | -5.54 | 62.5 | 41.3 | 19.6 |
| Total Liabilities & Shareholders' Equity | 6.93 | 2.4 | 70.8 | 48.8 | 26.5 |
| Total Common Shares Outstanding |